Citizens JMP raised the firm’s price target on DBV Technologies (DBVT) to $21 from $15 and keeps an Outperform rating on the shares. Xolair’s food allergy launch has more than 50K patients on drug within the first year despite some key hindrances, which may be limiting its use in Viaskin Peanut’s target 1-7 year old population, the analyst tells investors in a research note. The firm sees the Phase 3 VITESSE data in 4-7 year olds in Q4 as the next key catalyst for shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Buy Rating for DBV Technologies Driven by Promising Viaskin Peanut Potential and Strong Market Opportunity
- DBV Technologies files to sell 289.01M ordinary shares for holders
- DBV Technologies price target raised to $16 from $7 at H.C. Wainwright
- DBV Technologies price target raised to $15 from $10 at Citizens JMP
- DBVT Upcoming Earnings Report: What to Expect?